论文部分内容阅读
目的比较恶性肿瘤患者和健康人来源的细胞因子诱导的杀伤细胞(CIK cells)体外抗瘤效应和临床疗效。方法恶性肿瘤患者(n=12)和健康人(n=12)外周血单个核细胞(PBMC)经IFN-γ、CD3 Ab、IL-1和IL-2体外诱导获得CIK,锥虫蓝染色检测体外增殖,CCK-8检测抑瘤活性,流式细胞术检测细胞表型,PCR分析CIK在患者外周血的代谢,最后比较近期疗效。结果健康人CIK较患者CIK体外增殖快、CD3~+CD56~+比例高且抑瘤效应强(P<0.01),能在患者外周血中存在5~8周并有效改善其免疫机能,两者近期疗效无显著差异。结论健康人CIK治疗恶性肿瘤高效可行,有着广阔的临床应用前景。
Objective To compare the anti-tumor effect and clinical efficacy of cytokine-induced killer cells (CIK cells) derived from malignant and healthy human beings. Methods Peripheral blood mononuclear cells (PBMC) from malignant tumor patients (n = 12) and healthy people (n = 12) were induced by IFN-γ, CD3 Ab, IL-1 and IL- Proliferation in vitro, CCK-8 detection of anti-tumor activity, flow cytometry cell phenotype, PCR analysis of CIK in patients with peripheral blood metabolism, and finally the more recent curative effect. Results Compared with CIK, the CIK of healthy people proliferated rapidly in vitro, the ratio of CD3 + CD56 + was high and the anti-tumor effect was strong (P <0.01). CIK could be present in the peripheral blood of patients for 5-8 weeks and effectively improved its immune function. No significant difference in the recent efficacy. Conclusion The treatment of CIK in healthy people is highly effective and feasible, and has a promising prospect in clinical application.